Diagnostic Services: Mahajan, Neuberg Form North JV

Diagnostic services in North India are set for a new integrated network after Mahajan Imaging & Labs and Neuberg Diagnostics announced a strategic joint venture on August 31, 2026. The venture connects Mahajan’s radiology and nuclear-medicine footprint with Neuberg’s pathology, genomics, laboratory operations and digital infrastructure. Its immediate task is to integrate existing labs in Noida, Lucknow and Jammu before expanding deeper into tier-II and non-metro markets.

Everyone else is reporting a partnership; we are explaining the operating mechanism. The deal is not merely a referral agreement. Mahajan becomes Neuberg’s exclusive partner across seven states and territories, existing laboratory operations change hands, digital systems must be connected, and the combined platform plans logistics, artificial-intelligence quality control and specialised centres.

What the Mahajan–Neuberg joint venture includes

The companies said Mahajan Imaging will serve as Neuberg’s exclusive partner in the National Capital Region, Uttar Pradesh, Rajasthan, Punjab, Haryana, Himachal Pradesh and Jammu & Kashmir. The JV will operate under the Mahajan Imaging & Neuberg Labs name, subject to approvals and licences.

It will take over Neuberg’s existing laboratory operations in Noida, Lucknow and Jammu. That gives the venture a starting footprint instead of requiring it to build every hub from zero. Mahajan contributes a radiology and nuclear-medicine network across NCR and Jaipur, while Neuberg brings access to more than 200 accredited laboratories and its digital systems.

The partners did not disclose ownership proportions, transaction value or total capital outlay. That absence is important. The announcement establishes strategic scope and management intent, but readers cannot yet calculate the venture’s valuation, investment return or near-term financial contribution.

Primary information is available from Mahajan Imaging & Labs and Neuberg Diagnostics. Independent same-day reports from Mint, ETHealthworld and Indian Pharma Post corroborated the seven-market scope, initial laboratory locations and integrated-service plan.

Why diagnostic services are moving toward integration

Radiology creates images of structures inside the body through technologies such as MRI, CT, ultrasound, X-ray and PET-CT. Pathology examines blood, tissue and other samples. Genomics studies DNA, while proteomics and metabolomics examine proteins and small molecules involved in biological processes.

These disciplines answer different questions. A scan may show the location and size of a lesion, while pathology identifies its cellular characteristics. Genomic testing can reveal variants relevant to inherited risk or treatment selection. Clinicians often need several forms of evidence before making a decision.

An integrated diagnostic services model tries to connect those results into one pathway. The commercial benefit can come from shared collection points, logistics, digital reporting and referrals. The clinical benefit depends on whether systems preserve quality, turnaround time and clear specialist interpretation.

Harsh Mahajan, founder and chairman of Mahajan Imaging & Labs, said clinical decisions increasingly require imaging, pathology, molecular testing and genomics to be considered together. Neuberg founder G.S.K. Velu described the opportunity as a broader diagnostics presence built on pathology, genomics, wellness, IT infrastructure and operating experience.

How the North India expansion is supposed to work

The partners plan to invest in laboratory infrastructure, sample-collection networks and logistics. Their stated ideas include technology-led sample transit and drone-enabled delivery between remote collection centres and central reference laboratories. Those systems could widen reach, but they will need validation for route reliability, temperature control, chain of custody and local aviation rules.

The venture also intends to establish specialised Centres of Excellence and longevity centres in NCR. Proposed offerings include early-disease interception, preventive wellness and multi-omics profiling. The announced “Health Atlas” concept aims to combine genomic, proteomic, metabolomic and radiological information to establish a health baseline and identify potential abnormalities.

These are ambitious services. Their value will depend on clinical evidence, appropriate patient selection, informed consent and transparent explanation of uncertain findings. Broad testing can uncover variants or biomarkers whose significance is unclear, so more data does not automatically mean a better decision.

Where artificial intelligence may fit

Kabir Mahajan, named chief executive of the venture, said execution would include integrating digital systems, reducing sample turnaround times and using artificial intelligence for quality control and reporting. AI may flag image artefacts, detect inconsistent laboratory patterns, route work or help specialists prioritise cases.

AI cannot independently replace the accountable radiologist or pathologist. Diagnostic outputs can influence surgery, drug treatment and long-term monitoring, so the provider must validate models on relevant populations, monitor errors and document human review. Patient data also requires strong access controls and retention policies.

The most practical early gains may be operational: matching records, tracking samples, reducing duplicate data entry and alerting teams when a result is delayed. These improvements are less dramatic than autonomous diagnosis, but they can directly affect reliability and turnaround time.

What patients could gain—and what remains uncertain

Patients may gain access to imaging and laboratory tests through a single network, fewer transfers between providers and more coordinated reports. Doctors may receive a broader evidence set without separately retrieving results from several systems. Smaller cities could benefit if collection and logistics connect them to reference laboratories.

However, the announcement does not guarantee that every centre will offer every service. Availability will vary by equipment, staffing, licences and local demand. The companies have not published a rollout calendar, price list, ownership split or capital budget.

Patients should therefore verify local accreditation, test availability, preparation instructions, turnaround time and the qualifications of the specialist signing the report. They should also ask whether a genomic or multi-omics test has clear clinical utility for their situation and how incidental findings will be handled.

Verified deal element	What is known	What is not yet disclosed
Geographic scope	Seven northern states and territories	Centre-by-centre rollout dates
Initial operations	Noida, Lucknow and Jammu labs	Capacity and investment per lab
Capabilities	Radiology, pathology, genomics, metabolomics, wellness	Exact test menu at each location
Technology	Digital integration, AI quality control, advanced logistics	Vendors, validation metrics and deployment timetable
Financial terms	Not disclosed	Ownership, valuation and total capital outlay

The business logic behind the JV

Diagnostic equipment and reference laboratories require high fixed investment. A broader network can spread those costs across more patients, while collection points and logistics direct samples to facilities with specialised equipment. Cross-referrals can also raise utilisation.

For Mahajan, the partnership adds pathology, genomics and laboratory depth without independently building every capability. For Neuberg, it offers regional clinical presence and an established imaging network. Exclusivity reduces overlap between their expansion efforts in the agreed territory.

Competition will remain intense. National chains, hospital laboratories and strong local providers compete on trust, price, speed and convenience. Icra expects organised diagnostic chains to record 12%–14% revenue growth in 2026–27, according to Mint, supported by preventive screening, non-metro expansion and demand for precision testing.

The sector’s financial discipline is also under scrutiny. Lapaas Voice recently covered Healthians’ first FY26 profit, which shows how scale, efficiency and unit economics shape diagnostic businesses. Neuberg’s wider company profile, including earlier expansion signals, is available in our Neuberg Diagnostics company record.

The Mahajan–Neuberg venture is an operating integration of imaging, laboratory testing and advanced diagnostics across seven northern markets. Its promise is a connected clinical pathway; its real test will be whether it improves access and turnaround time while preserving quality, consent and specialist accountability.

What happens next

The immediate milestones are regulatory approvals, transfer and integration of the three Neuberg laboratory operations, and alignment of booking, reporting and quality systems. The new management team must also define service availability across its network and recruit enough radiologists, pathologists, genetic counsellors and technicians.

Later milestones include collection-network expansion, Centres of Excellence, longevity facilities and proposed logistics technology. The companies will need to publish practical information—locations, test menus, prices and accreditation—before patients can assess the effect in their city.

Investors will watch utilisation, capital expenditure and whether referrals create profitable growth. Clinicians will focus on report quality and coordination. Patients will judge the venture more simply: whether it provides accurate results, reasonable prices and a smoother experience.

Quality safeguards that will matter

Network scale cannot substitute for laboratory and imaging standards. Equipment calibration, external quality assurance, specialist sign-off and documented corrective action are core operating controls. When samples travel longer distances, packaging, temperature and handover records become more important.

Digital integration also creates a patient-matching challenge. Names, dates of birth and identifiers must be reconciled without attaching a result to the wrong record. The venture will need audit trails for edits and clear escalation when systems disagree.

For advanced testing, consent must explain the purpose, limitations and possible incidental findings. Patients should know who can access their data and whether samples may be retained. Those safeguards will help determine whether integrated diagnostic services earn trust beyond the convenience of a larger network.

FAQs

What is the Mahajan Neuberg partnership?

It is a strategic joint venture combining Mahajan Imaging & Labs’ imaging network with Neuberg Diagnostics’ pathology, genomics and laboratory capabilities in North India.

Which regions are covered?

The announced exclusive territory covers NCR, Uttar Pradesh, Rajasthan, Punjab, Haryana, Himachal Pradesh and Jammu & Kashmir.

Which laboratories will be integrated first?

The venture is expected to take over and integrate Neuberg’s existing laboratory operations in Noida, Lucknow and Jammu.

Were the financial terms disclosed?

No. The companies did not disclose the ownership split, valuation or total capital outlay.